A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD

NCT03573817 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
122
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Mylan Inc.

Collaborators